Share this page!

Hilda Bastian, PhD Profile picture
Twitter logo
11 Jan, 4 tweets, 2 min read
Indonesia issued emergency use authorization for Sinovac's CoronaVac; spokesperson for BPOM (drug regulator) said the efficacy rate in the Indonesian phase 3 trial was 65% (trial of 1,600 people). jakartaglobe.id/news/indonesia… HT @bayukariastanto ...1/2
...Indonesia's decision was based on the vaccine having above the 50% minimum vaccine efficacy set by the WHO - while the virus is out of control in Jakarta.

Records on this vaccine: zotero.org/groups/2528572… 2/2
...The BPOM spokesperson, Penny Lukito, also announced that CoronaVac has been certified Halal. halosemarang.id/bpom-terbitkan…
...6 vaccines in addition to CoronaVac apparently authorized for Indonesia: Moderna, Novavax, Oxford/AstraZeneca, Sinopharm, Tozinameran (BNT/Pfizer). cnnindonesia.com/nasional/20210… HT @Stephanus_SJ

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Hilda Bastian, PhD

Hilda Bastian, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @hildabast

Hilda Bastian, PhD Profile picture
12 Jan
Press conference on results of Brazilian trial of CoronaVac, Sinovac's inactivated vaccine, cleared up the efficacy data & made the complexity of comparing a trial in healthcare professionals with others *really* clear: are they better at self-diagnosing Covid-19 symptoms?...1/n
...That's a central question now: does this trial capture more much "milder" infections than the others we've seen? They're suggesting it does & that drives down the apparent efficacy rate. Here's how the data plays out...2/n
...The trial's definition of symptomatic Covid-19: the first is a slide from the press conference (Portuguese), the second is from the English version of the trial protocol. The primary efficacy endpoint is regardless of whether the person had previous SARS-Cov-2 infection... 3/n ImageImage
Read 11 tweets
Hilda Bastian, PhD Profile picture
7 Jan
Some results from Brazilian phase 3 trial for Sinovac's inactivated Covid vaccine CoronaVac released at a press conference. Vaccine efficacy for mild symptomatic Covid-19: 78%, similar in people under & over 60 years. 0 moderate/severe/hospitalized... 1/n g1.globo.com/bemestar/vacin…
...For background: it's a trial in healthcare workers. The protocol was published here: trialsjournal.biomedcentral.com/articles/10.11… Collection of records on this vaccine here: zotero.org/groups/2528572… ....2/n
...Currently buying it from China, US$10 a dose: more than the Oxford vaccine ($3), half of Tozinameran (BNT/Pfizer). However supply of Oxford vax uncertain, whereas they already have drug regulator clearance for local manufacture of CoronaVac... 3/n www1.folha.uol.com.br/equilibrioesau…
Read 9 tweets
Hilda Bastian, PhD Profile picture
5 Jan
MHRA's (UK drug regulator) 57-page Public Assessment Report on Oxford/AstraZeneca vax is out: assets.publishing.service.gov.uk/government/upl… Like Oxford's publication, does not mention phase 3 trials in US & India (& so its serious adverse event), so not clear this is a selective trial report... 1/n
...Quality assessment of the drug & manufacturing facilities based on manufacturer reports & certifications, not MHRA inspections. Presumably as with Tozinameran (BNT/Pfizer vax), this would be done by the European Medicines Agency (EMA)...2/n
...Independent Batch Testing for the vaccine is undertaken UK National Institute for Biological Standards and Control (NIBSC). Temperature requirements confirmed (does not need super-freezing) ...3/n
Read 19 tweets
Hilda Bastian, PhD Profile picture
31 Dec 20
Statement from the UK Joint Committee on Vaccination & Immunisation (JCVI) on why they believe their strategy will achieve maximum impact: app.box.com/s/uwwn2dv4o2d0… 1/n
...They point out that most of the people who got sick with Covid-19 between 1st & 2nd doses of Tozinameran (BNT/Pfizer vax) did so in the 1st 2 weeks, so the efficacy after 2 weeks was 89% (95% CI 52-97%). But Pfizer stresses... 2/n
...that's only known for people who got their booster shot at 3 weeks, so it's unknown if it stays high for up to 3 months bloomberg.com/news/articles/… For the Oxford/AstraZeneca vax, they rely on a subgroup analysis - but the data isn't provided...3/n
Read 5 tweets
Hilda Bastian, PhD Profile picture
30 Dec 20
#tbt This is the amazing Anna Wessels Williams (1863-1954) in the early 1900s. Her sister nearly died in childbirth in 1887: distressed by her treatment, she entered medical school. She moved to lab work in 1894: her 1st major breakthrough came fast ...1/4 aai.org/About/History/…
...While her boss was on vacation, she solved the barrier to high-yield diphtheria vaccines. She followed that with a 2-year sabbatical at the Pasteur Institute, creating a rabies vaccine that would be mass-produced in the US. Next was a rabies test in 1905 used for decades...2/4
...She was on the frontlines of the 1918 influenza pandemic, developed a more accurate diagnostic test for trachoma, & co-published a major textbook as well as one of the early successful science books for the public in 1937 ... 3/4
Read 4 tweets
Hilda Bastian, PhD Profile picture
29 Dec 20
Well, dear readers, my take on "the winning formula" for Oxford/AstraZeneca did not age well. According to the Indian manufacturing partner, it isn't the "low"-dose-1st subgroup. It's another subgroup, perhaps a subgroup of a subgroup... livemint.com/science/health… HT @wogboy11 ..1/6
..The sweet spot he says is "a 2-to-3 months’ gap between dose 1 & dose 2". First let's recap their original data. They said intervals didn't make a difference. For the "standard"-"standard" group >8 wks apart vaccine efficacy was 65·6% (24·5 to 84·4). Ditto 6 weeks cutoff ..2/6
...The protocol doesn't limit the possible exploratory subgroup analyses ⬇️: so many ways they could have found a subgroup that hit this mark. Eg half the already-small "low"-dose-1st group had >12 wks apart: sliced off those perhaps? But I don't think that's the main point ..3/6
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @hildabast has new unrolls!

Check out other threads from @hildabast!

Read all threads by @hildabast